Basic Information
Revlimid Capsules 5mg
CAPSULE
Regulatory Information
SIN13662P
June 23, 2009
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XL04AX04
Company Information
Active Ingredients
Strength: 5.0 mg
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Women who are pregnant. - Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see sections 4.4 and 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Revlimid® (lenalidomide) as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Revlimid® (lenalidomide) in combination with dexamethasone is indicated for the treatment of previously untreated multiple myeloma patients who are not eligible for transplant. Revlimid® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.